Identification of non-small cell lung cancer (NSCLC) patients who benefit from treatment beyond progression with pembrolizumab from individual lesion response dynamics

Author:

Qi TimothyORCID,Cao YanguangORCID

Abstract

ABSTRACTBackgroundPembrolizumab is the recommended first-line treatment for non-small cell lung cancer (NSCLC) with no driver alterations and PD-L1 Tumor Proportion Score (TPS) ≥ 50%. Salvage therapies for patients who develop resistance in this setting are limited. Several retrospective studies have highlighted a subset of patients who benefit from pembrolizumab treatment beyond progression (TBP), but these results have yet to be validated in a rigorous prospective study.MethodsDue to the heterogeneity of within-patient responses to pembrolizumab, many patients can experience progressive disease while some of their lesions are still shrinking. We employed nonlinear mixed-effects modeling and virtual clinical trial simulations to evaluate the risk of unconditionally switching all progressors to salvage chemotherapy and to identify the subset of patients likely to benefit from pembrolizumab TBP. By using > 25,000 radiographic lesion diameter measurements from > 500 patients, we simulated individual lesion responses to pembrolizumab, chemotherapy, and pembrolizumab treatment failure followed by pembrolizumab TBP or salvage chemotherapy. We then assessed the benefit of pembrolizumab and chemotherapy in combination and explored a potential mechanism of intrapatient drug synergy called lesion-level independent action (LLIA).ResultsSwitching all progressors to salvage chemotherapy was suboptimal. Pembrolizumab TBP could extend progression-free survival (PFS) and control tumor burden more in nontarget progressors with fewer lesions prior to treatment initiation. Assuming LLIA but not patient-level independent action (PLIA) for combination therapy yielded longer PFS.ConclusionsPembrolizumab TBP may benefit a subset of patients with PD-L1-high, driver alteration-free NSCLC who experience nontarget progression, but prospective studies are warranted.

Publisher

Cold Spring Harbor Laboratory

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3